Atsena Therapeutics initiated part B of the phase 1/2 LIGHTHOUSE study investigating ATSN-201 for the treatment of X-linked retinoschisis, according to a press release.
The multicenter clinical trial will include nine adult patients and three pediatric patients with X-linked retinoschisis. At the recommendation of a data monitoring committee, patients will be dosed with ATSN-201 1E11 vg/mL, “a concentration that offered the optimal balance of tolerability and efficacy based on preliminary clinical results,” the release said.
The adult cohort will be divided into low-volume,